Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Perrigo Company plc's Expenses

Pharma Cost Trends: Corcept vs. Perrigo from 2014-2023

__timestampCorcept Therapeutics IncorporatedPerrigo Company plc
Wednesday, January 1, 20148820002613100000
Thursday, January 1, 201513610002891500000
Friday, January 1, 201620580003228800000
Sunday, January 1, 201735540002966700000
Monday, January 1, 201852150002900200000
Tuesday, January 1, 201955040003064100000
Wednesday, January 1, 202055820003248100000
Friday, January 1, 202152810002722500000
Saturday, January 1, 202253850002996200000
Sunday, January 1, 202364810002975200000
Loading chart...

Unleashing insights

Cost Insights: A Comparative Analysis of Corcept Therapeutics and Perrigo Company

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for Corcept Therapeutics Incorporated and Perrigo Company plc from 2014 to 2023. Over this period, Corcept Therapeutics has seen a significant increase in its cost of revenue, growing by approximately 635% from 2014 to 2023. In contrast, Perrigo Company has maintained a relatively stable cost structure, with fluctuations around the $3 billion mark.

Key Insights

  • Corcept Therapeutics: Starting at a modest $882,000 in 2014, the company's cost of revenue surged to $6.48 million by 2023, reflecting its expanding operations and market presence.
  • Perrigo Company: Despite minor annual variations, Perrigo's cost of revenue remained robust, peaking at $3.25 billion in 2020.

This comparative analysis highlights the dynamic nature of cost management in the pharmaceutical sector, offering valuable insights for strategic decision-making.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025